Detailed view for Rv0671

Basic information

TDR Targets ID: 6365
Mycobacterium tuberculosis, Possible conserved lipoprotein LpqP
Source Database / ID:  Tuberculist 

pI: 7.6644 | Length (AA): 280 | MW (Da): 29579 | Paralog Number: 1

Signal peptide: Y | GPI Anchor: | Predicted trans-membrane segments: 1

Druggability Group : DG1

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF10503   Esterase PHB depolymerase

Gene Ontology

Mouse over links to read term descriptions.
GO:0005576   extracellular region  
GO:0016787   hydrolase activity  

Metabolic Pathways

This gene is not mapped to any metabolic pathway in KEGG.

Structural information

Modbase 3D models:

There are 5 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
24 278 3d0k (A) 14 285 19.00 0 0.52 1.07491 -0.1
40 279 2h1i (A) 0 202 16.00 0 1 0.855343 -0.43
44 160 1f6w (A) 84 207 18.00 0 0.39 0.551057 0.01
46 171 3wyd (A) 305 424 37.00 0.00000013 1 0.7046 -0.12
48 171 5x6s (A) 21 144 29.00 0.00058 1 0.755457 -0.6

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

Upregulation Percent Ranking Stage Dataset
Mid 40-60% percentile Dormant phase, Dormant phase. hasan murphy
Show/Hide expression data references
  • murphy Identification of gene targets against dormant phase Mycobacterium tuberculosis infections.
  • hasan Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis.

Orthologs

Ortholog group members (OG5_135121)

Species Accession Gene Product
Leishmania braziliensis LbrM.35.4890   hypothetical protein, conserved
Leishmania donovani LdBPK_364870.1   Esterase PHB depolymerase, putative
Leishmania infantum LinJ.36.4870   hypothetical protein, conserved
Leishmania major LmjF.36.4640   hypothetical protein, conserved
Leishmania mexicana LmxM.36.4640   hypothetical protein, conserved
Mycobacterium leprae ML0715   Possible esterase lipoprotein LpqC
Mycobacterium tuberculosis Rv3298c   Possible esterase lipoprotein LpqC
Mycobacterium tuberculosis Rv0671   Possible conserved lipoprotein LpqP
Mycobacterium ulcerans MUL_0752   lipoprotein LpqP
Mycobacterium ulcerans MUL_2651   esterase lipoprotein LpqC
Trypanosoma brucei gambiense Tbg972.10.12200   hypothetical protein, conserved
Trypanosoma brucei Tb927.10.10000   hypothetical protein, conserved
Trypanosoma congolense TcIL3000_10_8360   hypothetical protein, conserved
Trypanosoma cruzi TcCLB.508307.180   hypothetical protein, conserved

Essentiality

Rv0671 has direct evidence of essentiality
Gene/Ortholog Organism Phenotype Source Study
mtu3357 Mycobacterium tuberculosis non-essential nmpdr
mtu683 this record Mycobacterium tuberculosis non-essential nmpdr
Tb927.10.10000 Trypanosoma brucei no significant loss or gain of fitness in bloodstream forms (3 days) alsford
Tb927.10.10000 Trypanosoma brucei significant loss of fitness in bloodstream forms (6 days) alsford
Tb927.10.10000 Trypanosoma brucei significant loss of fitness in procyclic forms alsford
Tb927.10.10000 Trypanosoma brucei no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms alsford
Show/Hide essentiality data references
  • shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan
  • yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database
  • gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84
  • goodall The Essential Genome of Escherichia coli K-12 (Transposon directed high-throughput mutagenesis) Goodall, Emily CA, et al. "The essential genome of Escherichia coli K-12." mBio 9.1 (2018): e02096-17.
  • alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924
  • nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource
  • plasmo Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Bushell, Ellen, et al. "Functional profiling of a Plasmodium genome reveals an abundance of essential genes." Cell 170.2 (2017): 260-272.
  • neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs
  • keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection
  • sidik A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Sidik, Saima M., et al. "A genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genes." Cell 166.6 (2016): 1423-1435.
  • blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930
  • wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170

Phenotypes and Validation (curated)

We have no manually annotated phenotypes for this target. What does this mean? / Care to help?

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

No validation data for this target

Associated compounds / Druggability

Known modulators for this target

No chemical compounds associated to this gene

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
No additional associated druggable targets
Obtained from network model
No druggable targets predicted through repurposing network model

Assayability

Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

No literature references available for this target.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier Rv0671 (Mycobacterium tuberculosis), Possible conserved lipoprotein LpqP
Title for this comment
Comment